GlassScriptPhysician profile
Joseph C Lu
NPI 1407243538
$1,793.52
in general payments reported to CMS, 2019-2025
14 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $48.51 · 2021: $57.19 · 2022: $273 · 2023: $258 · 2024: $243 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.30 |
| Education | $116.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $677.11 | 2022-2025 | |
| Eisai INC. | $198.76 | 2025 | |
| Mdd US Operations, LLC | $167.54 | 2025 | |
| Acadia Pharmaceuticals INC | $141.13 | 2024-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $136.72 | 2025 | Austedo Xr |
| Lilly USA, LLC | $70.05 | 2025 | Kisunla |
| Kyowa Kirin, INC. | $69.91 | 2022-2024 | Nourianz |
| Ucb, INC. | $63.51 | 2020-2025 | Rystiggo |
| Neurocrine Biosciences, INC. | $57.19 | 2021 | |
| Amneal Pharmaceuticals LLC | $54.82 | 2025 | Crexont |
| Axsome Therapeutics, INC. | $54.01 | 2025 | Symbravo |
| Amgen INC. | $52.76 | 2025 | Uplizna |
| Averitas Pharma INC. | $26.26 | 2024 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $23.75 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.